Asabys Partners, a venture capital fund created in Barcelona in early 2019, has announced its first investments: €1.5 million in spin-off Ona Therapeutics and €8 million in Psious, a round co-led by Caixa Capital Risc with participation from other investors, including Sabadell Venture Capital.

With this funding, Ona Therapeutics will begin development of a new drug to treat metastatic cancer, while Psious will complete development of its virtual reality solution to treat anxiety disorders.

Asabys has kicked off with €30 million in committed capital, although its goal is to put together €70 million to invest in roughly 15 biomedical companies over the next 5 years, both in Spain and abroad. Banco Sabadell is the main investor.

In addition to its team, Asabys has several venture partners from the sector, including Eva Méndez, who specialises in drug discovery; Judit Anido, co-founder of Mosaic Biomedicals and CataloniaBio & HealthTech board member; François Salmon, expert in medical devices and current CEO of Anaconda; and Jordi Carrera, co-founder of STAT-Dx.

Photo: Clara Campàs and Josep Lluís Sanfeliu, Asabys founding partners, at their offices on Passeig de Gràcia in Barcelona - © Asabys Partners

We recommend the videointerview by CataloniaBioHT: